Mangalam Drugs and Organics' Q4 FY 2025-26 Quarterly Results

Result Summary

• Mangalam Drugs and Organics Ltd reported a 15.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 8.0%.
• Its expenses for the quarter were up by 17.9% QoQ and 12.6% YoY.
• The net profit increased 36.4% QoQ and decreased 22466.7% YoY.
• The earnings per share (EPS) of Mangalam Drugs and Organics Ltd declined at 8.48 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mangalam Drugs and Organics Ltd is a pharmaceutical company engaged in the manufacture and sale of bulk drugs and pharmaceutical formulations. The company specializes in producing anti-malarial APIs (Active Pharmaceutical Ingredients) and formulations, which are critical components in the fight against malaria. The pharmaceutical industry is highly competitive and is subject to stringent regulations. Due to the nature of its business, Mangalam Drugs and Organics Ltd is influenced by factors such as regulatory changes, market demand, and the cost of raw materials. Recent developments in the industry have focused on innovation in drug formulation and increased demand for generic drugs.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Mangalam Drugs and Organics Ltd reported a total income of ₹67.38 crores. This represents a quarter-over-quarter (QoQ) increase of 15.0% from ₹58.60 crores in Q3FY26. However, on a year-over-year (YoY) basis, total income decreased by 8.0% from ₹73.25 crores in Q4FY25. The revenue trends indicate fluctuations over the quarters, with a notable increase in QoQ revenue but a decline in YoY revenue. These changes reflect the dynamic nature of the market and the company's sales performance over time.

Profitability

The financial data for Q4FY26 shows that Mangalam Drugs and Organics Ltd had a loss, with a Profit Before Tax (PBT) of -₹13.27 crores. This marks a significant increase in losses compared to the previous quarter (Q3FY26), where the PBT was -₹9.84 crores, resulting in a 34.9% increase in losses QoQ. Compared to Q4FY25, when the company had a PBT of ₹1.63 crores, there is a drastic YoY decline of 914.1%. The Profit After Tax (PAT) also shows increased losses, with -₹13.42 crores in Q4FY26 versus -₹9.84 crores in Q3FY26, amounting to a 36.4% QoQ increase in losses. Compared to Q4FY25’s PAT of ₹0.06 crores, the YoY decline is substantial at 22466.7%. Earnings per Share (EPS) followed a similar trend, with a value of -₹8.48 in Q4FY26 compared to -₹6.21 in Q3FY26 and ₹0.04 in Q4FY25, reflecting a 36.6% QoQ decline and a 21300.0% YoY decline.

Operating Metrics

The total expenses for Mangalam Drugs and Organics Ltd in Q4FY26 were ₹80.65 crores, which is a 17.9% increase QoQ from ₹68.43 crores in Q3FY26. On a YoY basis, total expenses increased by 12.6% from ₹71.61 crores in Q4FY25. The company's tax expense was recorded at ₹0.15 crores in Q4FY26, whereas it was nil in Q3FY26 and ₹1.58 crores in Q4FY25, showing a significant YoY decrease of 90.5%. The financial performance during the quarter indicates increased operational costs and tax expenses, contributing to the overall financial position of the company. The trends observed in operating metrics provide insight into the cost structure and financial health of the company during this period.